Corrigendum: Perspective: A Framework to Screen Pediatric and Adolescent Hematopoietic Cellular Therapy Patients for Organ Dysfunction: Time for a Multi-Disciplinary and Longitudinal Approach

In the original article, there was a mistake in Table 2 . Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patients as published.

Table 2.

Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patients^ab.

Score+	0	1	2	3	4	5
Respiratory c Oxygen support on the HCT floors PaO2/FiO2 (P/F) ratio SpO2/FiO2 (P/F) ratio	Room air	Blow-by oxygen and ≥400 ≥292	Nasal Cannula or 300-399 264-291	NIV or 200-299 221-263	MV and/or 100-199 with respiratory support 148-220 with respiratory support	MV and/or <100 with respiratory support <148 with respiratory support
CV (MAP by age group, mmHg)d < 1 month 1-11 months 12-23 months 24-59 months 60-143 months 144-215 months >216 months or Vasoactive infusion, μg/kg/min	≥ 46 ≥ 55 ≥ 60 ≥ 62 ≥ 65 ≥ 67 ≥ 70	< 46 < 55 < 60 < 62 < 65 < 67 < 70	Dopamine hydrochloride < 5 or dobutamine hydrochloride (any)	Dopamine hydrochloride 5-9.9 or epinephrine < 0.1 or norepinephrine bitartrate ≤ 0.1	Dopamine hydrochloride 10-14.9 or epinephrine 0.1-0.2 or norepinephrine bitartrate 0.1-0.2	Dopamine hydrochloride > 15 or epinephrine > 0.2 or norepinephrine bitartrate > 0.2
Renal KDIGO AKI Criteria Patients must have one of the following 1. Increase in baseline Serum creatinine (bSCr) ≥ 0.3 mg/dL within 48 hrs 2. Increase in bSCr ≥ 1.5x baseline that is known or presumed to have occurred within past 7 d 3. Urine volume < 0.5 mL/kg/hr for 6 hr	Baseline (No AKI)			KDIGO 1 1.5-1.9 x bSCr or Cr increase > 0.3 mg/dL or Urine volume < 0.5 mL/kg/hr for 6-12 hours	KDIGO 2 2-2.9 x bSCr or Urine volume < 0.5 mL/kg/hr for >12 hours	KDIGO 3 >3 x bSCr or Cr > 4 mg/dL or Initiation of RRT or Urine volume < 0.5 mL/kg/hr for > 24 hours or Anuria> 12 hours
Renal Weight gain – after diuretics	Baseline	2-5%	>5-10%	>10%	Persistent rise >10%	RRT
Hepatic Total Bilirubin	Baseline			≥ 2	Doubles in 48h	Doubles in 24h
Hematologic INR or Refractory Thrombocytopenia	<1.2	1.2 -1.5 < 3 days	>1.5-1.9 3-7 days	≥2	Need replacement of factors > 7 days	Active Bleeding
CNS CAPDe	Baseline or <9	Initial increase from baseline, but < 9	Sequential increase from baseline, but < 9	≥ 9	Sequential increase > 9	≥ 9 and/or recent/active CVA, PRES, or seizures
Immune Reconstitution f ANC ALC Acute GVHD (75) Active infection	>1500/mm3 >1500/mm3 None None	>1000-1500/mm3 >1000-1500/mm3 Stage 1 H/o clinically significant infection	500-1000/mm3 >800 -1000/mm3 Stage 2 Active controlled	< 500/mm3 500-800/mm3 Stage 3 Active uncontrolled	<200/mm3 <500/mm3 Stage 4 Multiple active/uncontrolled infections	<100/mm3 <200/mm3 Stage 4 Multiple active/uncontrolled infections

a. May be performed weekly and if clinically significant deterioration. Use the worst value in preceding 24-hour period for each variable b. If concern for pMODS, recommend further screening for endotheliopathies such as CLS, ES, TMA, DAH, IPS, and/or SOS. c. P/F ratio to be used when arterial blood gas is available. Otherwise, use S/F ratio. d. MAP = (1/3 x SBP) + (2/3 x DBP) e. CAPD change from baseline should also be taken into consideration when using CAPD score. e. ANC: absolute neutrophil count [white blood cell count (k/uL) x (%neutrophils+ bands) x 10 f. ALC: absolute lymphocyte count [white blood cell count (k/uL) x (% lymphocytes) x 10 + patients receiving end of life care may be delineated with an organ score and “E” (example 4E); this designation is intended to retain awareness of specific goals of care and explicitly state rationale when invasive organ support interventions are not initiated. f. Assign the highest score if any 1 criteria is met in this category.

The following in Table 2 has been corrected:

Respiratory: Score 0 and Score 2; CV: Score 2; Renal: Score 4; Hematologic: Score 0, Score 1, Score 2, and Score 3; CNS: Score 0 and Score 4; Immune Reconstitution: Score 1 and Score 2 and Footnote f.

The corrected Table 2. Possible Screening for pMODS for Pediatric and Adolescent-Young Adult (AYA) HCT Patients appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.